UK medtech company Ultromics has received US Food and Drug Administration (FDA) clearance for EchoGo Heart Failure, its artificial intelligence (AI) solution for echocardiography used in the diagnosis of heart failure with preserved ejection fraction (HFpEF).
EchoGo Heart Failure uses machine learning algorithms to analyze images from echocardiograms and provide detailed assessments of left ventricular function, helping to improve the accuracy and speed of diagnosis for HFpEF, a condition in which the heart continues to pump blood but is not as efficient as it should be. This is the first FDA clearance for an AI tool used in the diagnosis of HFpEF, and it has the potential to significantly improve patient care and outcomes.
Check out the full article by Med-Tech Innovation here: med-technews.com